Vejle Hospital
sygehuslillebaelt.dkTotal trials
92
Active
21
Phase 3
6
Total enrollment
20,823
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oxaliplatin | — | — | — | — | 4 | ||
| Capecitabine | — | — | — | — | 4 | ||
| Dronabinol 2.5mg | — | — | — | — | — | 1 | |
| Capecitabine 825 mg/m2 twice daily on weekdays | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 5 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| Calcium folinate | — | — | — | — | — | 1 | |
| Senicapoc | — | — | — | — | — | 1 |
Next readouts
- 2023-06
- 2025-03-31
- 2026-09
- 2026-12
- 2028-12
Top conditions
- Colorectal Cancer10
- Breast Cancer8
- Ovarian Cancer7
- Metastatic Colorectal Cancer5
- Multiple Myeloma5
- Myopia5
- Rectal Cancer4
- Cancer4
Frequently asked questions about Vejle Hospital
- How many clinical trials does Vejle Hospital have on ClinicalTrials.gov?
- Vejle Hospital is listed as the lead sponsor on 92 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vejle Hospital's trials are in Phase 3?
- 6 of Vejle Hospital's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Vejle Hospital focus on?
- Vejle Hospital's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Breast Cancer, Ovarian Cancer, Metastatic Colorectal Cancer, Multiple Myeloma.
- When are Vejle Hospital's next clinical trial readouts?
- Vejle Hospital has 5 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer”, expected around 2023-06.